| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/27/2002 | US20020082252 Methods and compositions for treating conditions of the central and peripheral nervous systems using non-synaptic mechanisms |
| 06/27/2002 | US20020082241 Adenosine as antithrombotic |
| 06/27/2002 | US20020082240 Method for treating restenosis with a2a adenosine receptor agonists |
| 06/27/2002 | US20020082235 Inhibition of binding of hox and homeodomain-containing proteins and uses thereof |
| 06/27/2002 | US20020082234 Novel prokaryotic polynucleotides, polypeptides and their uses |
| 06/27/2002 | US20020082221 Nitric-oxide releasing lipid molecules selected from phosphoglycerides, lipids having a sphingosine base as a backbone, a monoglyceride, a diglyceride, a glycosylacylglycerol and a sterol containing S-N=O, N-N=O or |
| 06/27/2002 | US20020082211 Human presenilin variant |
| 06/27/2002 | US20020082205 Human FGF-23 gene and gene expression products |
| 06/27/2002 | US20020082201 And pharmaceutically acceptable surfactant including sodium lauryl sulfate, buffering agent to provide pH of 3.0-7.0, 0.5-10.0 weight percent colloidal silicon dioxide |
| 06/27/2002 | US20020082193 Inhibition of mitochondrial calcium/sodium antiporter |
| 06/27/2002 | US20020082190 Amino acid sequences of the transport proteins encoded by genes within the human genome; isolated peptide and nucleic acid molecules, methods of identifying orthologs, paralogs and modulators of the kinase peptides; brain disorders |
| 06/27/2002 | US20020081695 Nucleotide sequences coding polypeptide for use in the treatment of blood disorders, gout, kidney stones, Lesch-Nyhan syndrome, renal failure and uricaciduria |
| 06/27/2002 | US20020081659 Nucleic acids, proteins and antibodies |
| 06/27/2002 | US20020081653 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 06/27/2002 | US20020081649 Peptide for use in human therapeutics and diagnostics; for use as a antitumor agent |
| 06/27/2002 | US20020081648 Peptide for use in human thereapeutics and diagnostics |
| 06/27/2002 | US20020081645 Coding or classification of prion sample; obtain sample, monitor physical properties of sample, compare to control |
| 06/27/2002 | US20020081633 Methods for using 22045, a human cyclic nucleotide phosphodiesterase |
| 06/27/2002 | US20020081623 Chemotactic cytokine |
| 06/27/2002 | US20020081613 Detecting cancer in a tissue sample; obtain tissue sample, screen for preferential marker, presence of marker indicates cancer |
| 06/27/2002 | US20020081601 Methods and compositions for diagnosis and treatment of cancer based on the transcription factor ets2 |
| 06/27/2002 | US20020081585 Compounds for detection an inflammatory bowel disease |
| 06/27/2002 | US20020081578 Nucleotide sequences coding preferential polypeptide for as anticarcinogenic agents |
| 06/27/2002 | US20020081338 Composition for treating dry eye |
| 06/27/2002 | US20020081328 Zinc chloride unit dose packaging, applicator, and method of use in treating cancer and other skin diseases |
| 06/27/2002 | US20020081315 Methods and compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
| 06/27/2002 | US20020081314 Starch and protein from a mixture of embryo bud and seed coat of rice and fruit body of ganoderma lucidum are decomposed by aspergills oryzae with added B vitamins, and the enzyme retain their catalytic activity; prevent autoimmune diabetes |
| 06/27/2002 | US20020081299 Hair cell disorders |
| 06/27/2002 | US20020081296 Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3 and TACI |
| 06/27/2002 | US20020081290 Protein kinase homologs |
| 06/27/2002 | US20020081285 Treatment for diabetes |
| 06/27/2002 | US20020081263 Methods for decreasing beta amyloid protein |
| 06/27/2002 | DE10063884A1 Pharmaceutical preparation, useful for the treatment of cardiovascular and pulmonary diseases, comprises benzothienopyrimidine derivatives and calcium antagonists |
| 06/27/2002 | DE10061195A1 Verwendung von Abformmassen zur Herstellung von Behandlungsvorrichtungen Use of impression materials for the production of treatment devices |
| 06/27/2002 | CA2714357A1 Mutations in neuronal gene sodium-channel alpha1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus |
| 06/27/2002 | CA2433308A1 Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein staau_r4 |
| 06/27/2002 | CA2433165A1 Methods for reducing chronic stress in mammals |
| 06/27/2002 | CA2433027A1 Nucleic acid-associated proteins |
| 06/27/2002 | CA2433018A1 Thiazolyl inhibitors of tec family tyrosine kinases |
| 06/27/2002 | CA2432762A1 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof |
| 06/27/2002 | CA2432760A1 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof |
| 06/27/2002 | CA2432638A1 Therapeutic combination of amlodipine and benazepril |
| 06/27/2002 | CA2432282A1 Therapeutic combination of amlodipine and benazepril/benazeprilat |
| 06/27/2002 | CA2432265A1 Methods and compositions for protecting and restoring skin using selective mmp inhibitors |
| 06/27/2002 | CA2432036A1 Means for the diagnosis and therapy of ctcl |
| 06/27/2002 | CA2431990A1 Method for modulating the binding activity of a novel icam-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes |
| 06/27/2002 | CA2431985A1 Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
| 06/27/2002 | CA2431891A1 Mutations in neuronal gene sodium-channel alpha 1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus |
| 06/27/2002 | CA2431820A1 Replication assay for detecting anti-viral substances |
| 06/27/2002 | CA2431147A1 Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) |
| 06/27/2002 | CA2431139A1 Oxidoreductases |
| 06/27/2002 | CA2431077A1 Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives |
| 06/27/2002 | CA2431074A1 Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (1) |
| 06/27/2002 | CA2430918A1 Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds |
| 06/27/2002 | CA2430754A1 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 06/27/2002 | CA2430595A1 Dissociated glucocorticoid receptor antagonists for the treatment of glucocorticoid associated side-effect |
| 06/27/2002 | CA2429519A1 Novel human secreted proteins and polynucleotides encoding the same |
| 06/26/2002 | EP1217080A2 Methods, compositions and kits relating to cardiovascular disease |
| 06/26/2002 | EP1216707A1 New therapeutic uses of a SMR-1-peptide |
| 06/26/2002 | EP1216309A2 Methods for targeting rna molecules |
| 06/26/2002 | EP1216300A1 Methods and compositions relating to sodium channel beta1a subunits |
| 06/26/2002 | EP1216297A2 Double transgenic animals as models for neurodegenerative disease |
| 06/26/2002 | EP1216258A1 Factors having prion-binding activity in serum and plasma and agents to detect transmissible spongiform encephalopathitis |
| 06/26/2002 | EP1216257A1 Compounds for the treatment of ischemia |
| 06/26/2002 | EP1216241A1 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 06/26/2002 | EP1216238A2 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 06/26/2002 | EP1216225A2 Novel derivatives of dicarboxylic acid having pharmaceutical properties |
| 06/26/2002 | EP1216223A1 Novel dicarboxylic acid derivatives with pharmaceutical properties |
| 06/26/2002 | EP1216222A2 Novel derivatives of dicarboxylic acid having pharmaceutical properties |
| 06/26/2002 | EP1216059A2 Composition for ivf |
| 06/26/2002 | EP1216056A1 Blocking immune response to a foreign antigen using an antagonist which binds to cd20 |
| 06/26/2002 | EP1216052A1 Combination of c1-inh and lung surfactant for the treatment of respiratory disorders |
| 06/26/2002 | EP1216048A2 Solid lipid formulations comprising an inhibitor of lipases and a fatty acid ester of polyols |
| 06/26/2002 | EP1216047A2 Novel combination of loteprednol and beta2-adrenoceptor agonists |
| 06/26/2002 | EP1216046A2 Novel combination of loteprednol and antihistamines |
| 06/26/2002 | EP1216044A1 Compositions having improved stability |
| 06/26/2002 | EP1216043A1 Retard form containing alpha-lipoic acid (derivatives) |
| 06/26/2002 | EP1216039A2 Novel combination for the treatment of sexual dysfunction |
| 06/26/2002 | EP1216038A2 Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
| 06/26/2002 | EP1216037A2 Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents |
| 06/26/2002 | EP1216030A1 Anti-inflammatory pharmaceutical formulations |
| 06/26/2002 | EP1216026A1 Compositions of tocol-soluble therapeutics |
| 06/26/2002 | EP1216025A1 Dispersion formulations containing lipase inhibitors |
| 06/26/2002 | EP1216024A1 Formulation for menopausal women |
| 06/26/2002 | EP1143998A4 Treatment of hypertension |
| 06/26/2002 | EP1073414B1 Use of pharmaceutical compositions capable of being gelled in periodontology |
| 06/26/2002 | EP1051155B1 Nasal solutions |
| 06/26/2002 | EP0998288B1 Compositions containing capsaicin or capsaicin analogues and a local anesthetic |
| 06/26/2002 | EP0912895A4 Method for monitoring t-cell reactivity |
| 06/26/2002 | EP0904094A4 Treatment of bone disorders with adrenomedullin |
| 06/26/2002 | EP0822812B1 Topical treatment and prevention of sagging subcutaneous muscle and overlying cutaneous tissue using acetylcholine precursors and catecholamines |
| 06/26/2002 | EP0754050B1 Anti gram positive bacterial methods and materials |
| 06/26/2002 | EP0691814B1 Method and composition for treatment of osteoporosis |
| 06/26/2002 | EP0574391B1 Antibodies against the urokinase receptor and their use |
| 06/26/2002 | CN1355881A Growth differentiation factor inhibitors and uses therefor |
| 06/26/2002 | CN1355850A Hyaluronidase from hirudinaria manillensis, isolation, purification and recombinant method of production |
| 06/26/2002 | CN1355813A Peptide having preptin functionality |
| 06/26/2002 | CN1355811A Integrain receptor antagaonists |
| 06/26/2002 | CN1355711A Method for inhibiting brain tumor growth |
| 06/26/2002 | CN1355706A 因子 Factor |